Spironolactone for Hidradenitis Suppurativa

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate if the drug spironolactone - which is used to treat acne and male pattern hair growth in women - is effective in treating hidradenitis suppurativa in females and which dose of the drug works the best. Participation in this study will take about 4 clinic visits over approximately 7 months with the option to continue for longer if desired.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04100083
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Withdrawn
Phase	Phase 4
Start date	September 21, 2020
Completion date	June 21, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02904902` - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa	Phase 3
Completed	`NCT03628924` - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 2
Not yet recruiting	`NCT05531747` - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa	N/A
Recruiting	`NCT06028230` - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Completed	`NCT03275870` - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Phase 1/Phase 2
Completed	`NCT03248531` - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	Phase 2
Completed	`NCT00329823` - Etanercept in Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT05710393` - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed	`NCT04019041` - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa	Phase 2
Completed	`NCT05286567` - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.	Phase 1
Withdrawn	`NCT03929835` - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa	Phase 2
Terminated	`NCT04325607` - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa	N/A
Terminated	`NCT03238469` - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa	N/A
Completed	`NCT04449354` - HidraWear AX HS Study	N/A
Recruiting	`NCT06123429` - Mindfulness in Hidradenitis Suppurativa	N/A
Recruiting	`NCT05934825` - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa	Phase 1/Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT06046729` - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2
Completed	`NCT01516749` - Anakinra as a Treatment for Hydradenitis Suppurativa	Phase 2